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ABSTRACT
ObjeCtive
To evaluate the effectiveness of feedback on safety of 
prescribing compared with moderately enhanced 
usual care.
Design
Three arm, highly pragmatic cluster randomised trial.
setting anD partiCipants
262/278 (94%) primary care practices in three Scottish 
health boards.
interventiOns
Practices were randomised to: “usual care,” consisting 
of emailed educational material with support for 
searching to identify patients (88 practices at 
baseline, 86 analysed); usual care plus feedback on 
practice’s high risk prescribing sent quarterly on five 
occasions (87 practices, 86 analysed); or usual care 
plus the same feedback incorporating a behavioural 
change component (87 practices, 86 analysed).
Main OutCOMe Measures
The primary outcome was a patient level composite of 
six prescribing measures relating to high risk use of 
antipsychotics, non-steroidal anti-inflammatories, and 
antiplatelets. Secondary outcomes were the six 
individual measures. The primary analysis compared 
high risk prescribing in the two feedback arms against 
usual care at 15 months. Secondary analyses examined 
immediate change and change in trend of high risk 
prescribing associated with implementation of the 
intervention within each arm.
results
In the primary analysis, high risk prescribing as 
measured by the primary outcome fell from 6.0% 
(3332/55 896) to 5.1% (2845/55 872) in the usual care 
arm, compared with 5.9% (3341/56 194) to 4.6% 
(2587/56 478) in the feedback only arm (odds ratio 
0.88 (95% confidence interval 0.80 to 0.96) compared 
with usual care; P=0.007) and 6.2% (3634/58 569) to 
4.6% (2686/58 582) in the feedback plus behavioural 
change component arm (0.86 (0.78 to 0.95); P=0.002). 
In the pre-specified secondary analysis of change in 
trend within each arm, the usual care educational 
intervention had no effect on the existing declining 
trend in high risk prescribing. Both types of feedback 
were associated with significantly more rapid decline 
in high risk prescribing after the intervention 
compared with before.
COnClusiOns
Feedback of prescribing safety data was effective at 
reducing high risk prescribing. The intervention would 
be feasible to implement at scale in contexts where 
electronic health records are in general use.
trial registratiOn
 Clinical trials NCT01602705.
Introduction
Prescription drugs significantly improve patients’ out-
comes but are also a major cause of harm in both pri-
mary and hospital care.1-3 Approximately one in 20 
hospital admissions is caused by adverse drug events,1 
and at least half of these adverse drug events are pre-
ventable.4  The classes of drug most often implicated 
are antiplatelet drugs (including aspirin), diuretics, 
non-steroidal anti-inflammatory drugs, warfarin, opi-
oids, β blockers, angiotensin converting enzyme inhib-
itors/angiotensin receptor blockers, and hypoglycaemic 
drugs.4  Mortality has most frequently been associated 
with prescribing of non-steroidal anti-inflammatory 
and antiplatelet drugs,1  although several less com-
monly prescribed drugs also cause significant numbers 
of deaths, including antipsychotics in older people with 
dementia.5  Several consensus validated sets of 
 indicators of potentially inappropriate or high risk pri-
mary care prescribing are available,6-9 and high risk 
prescribing measured using these indicator sets is both 
common and variable between primary care practices 
(although not all such prescriptions will be inappro-
priate, as benefit will outweigh risk in at least some 
patients).10
Compared with hospital based studies, relatively few 
trials have looked at interventions to improve safety of 
WhAT IS AlReAdy knoWn on ThIS TopIC
Extensive evidence shows that audit and feedback is an effective intervention 
across a range of healthcare contexts and outcomes with small to moderate effects 
on the targeted quality or safety measure
Little evidence exists for the effectiveness of feedback in the context of prescribing 
safety, and more generally older audit and feedback trials were often 
methodologically limited
WhAT ThIS STudy AddS
This study used an intervention intended to reduce high risk prescribing, with 
comparison of different feedback formats (feedback only (arm 2) and feedback plus 
a theory informed behavioural change intervention (arm 3))
There was no evidence that a simple educational intervention with enhanced 
support for searching (usual care arm) significantly reduced the targeted high risk 
prescribing
Feedback in both formats was effective at reducing high risk prescribing compared 
with usual care (12% reduction in the odds of high risk prescribing in arm 2 and 14% 
in arm 3)
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prescribing in primary care, despite primary care physi-
cians in most developed countries being responsible for 
prescribing most community dispensed drugs. Much 
previous research has focused on pharmacist led inter-
ventions, although the effect of such interventions is 
variable and sometimes negative, at least partly owing 
to lack of integration with existing primary medical 
care.11 12  The PINCER trial found a statistically and 
 clinically significant reduction in targeted high risk 
 prescribing in a UK primary care context from imple-
menting an intervention combining educational out-
reach, feedback, and pharmacist led review of patients 
receiving high risk prescribing.13  More recently, the 
DQIP complex intervention comprising educational 
outreach, informatics to identify patients and support 
general practitioner led review, and small financial 
incentives to review was shown to reduce high risk pre-
scribing of non-steroidal anti-inflammatory and anti-
platelet drugs in UK primary care by approximately one 
third and was associated with significant reductions in 
emergency hospital admissions for gastrointestinal 
bleeding and heart failure.14 However, complex inter-
ventions such as PINCER and DQIP are relatively diffi-
cult and expensive to implement at scale.
Audit and feedback is an attractive intervention 
from this perspective because countries and health 
systems are increasingly creating comprehensive 
patient level datasets from electronic prescribing or 
electronic medical record data. In this context, feed-
back is relatively inexpensive to implement across 
whole systems, potentially allowing expensive inter-
ventions to be deployed more selectively. The 2012 
Cochrane review of trials of feedback found good 
 evidence that feedback is effective, but with a wide 
range of observed effects across studies.15  Although 
feedback interventions targeting prescribing were in 
general more effective than those targeting other 
 outcomes, only three trials included in the review 
examined the effect of feeding back data on safety of 
prescribing (two targeting benzodiazepine use16 17 
and one targeting risky non-steroidal anti-inflamma-
tory drug use18 ). None found feedback to be effective 
in reducing high risk prescribing, although only one 
trial was judged to have low risk of bias, emphasising 
that the evidence base for feedback is weak in the con-
text of prescribing safety.15
We aimed to add to the limited evidence about the 
effectiveness of feedback of data on prescribing safety 
and to fill gaps in the broader evidence about feedback 
identified by the most recent systematic review by car-
rying out a large trial (EFIPPS) of an intervention devel-
oped using both theory and empirical evidence to 
design the intervention in collaboration with clinicians 
and with comparison of different feedback formats, 
clearly defined primary outcomes, and adjustment for 
baseline performance.15 We therefore developed two 
theory informed formats for feedback on prescribing 
safety and tested their effectiveness at reducing high 
risk prescribing to patients compared with emailed 
 educational material in a three arm cluster randomised 
trial in 262 primary care practices in Scotland.
Methods
study design and participants
The study was a three group, parallel arm, pragmatic, 
cluster randomised controlled trial, described in more 
detail in the published protocol.19 Cluster randomisa-
tion was appropriate because feedback of high risk pre-
scribing data was at practice level. Practices were 
eligible if they were located in one of three Scottish 
health boards (geographically defined administrative 
organisations in the National Health Service in Scot-
land), if their registered list size was at least 250 patients 
(all practices smaller than this are unusual in the 
patients served—for example, by serving only homeless 
people), if at least 93% of their prescriptions could be 
linked to individual patients, and if they were estab-
lished before 1 January 2011. Practices were excluded 
from follow-up or analysis if they ceased to exist during 
the trial or if they merged with a practice from a differ-
ent arm during the trial.
Decisions about individual patient care remained the 
sole responsibility of the practice and the individual 
general practitioners working in it, so consent by 
patients was not required. No changes to the protocol, 
eligibility criteria, or outcomes occurred after the trial 
started.
randomisation and blinding
Practices were randomised to each arm on a 1:1:1 basis. 
As all practices were randomised at the same time, bal-
ancing the allocation sequence was unnecessary, but 
randomisation was stratified by participating health 
board (three strata, as boards have a remit to ensure 
that general practice prescribing is effective, safe, and 
value for money but vary in the amount of prescribing 
support provided to practices) and baseline high risk 
prescribing as measured by the primary outcome (in 
thirds). The trial statistical team used a random number 
generator to randomise each practice to one of three 
groups, and the Tayside Clinical Trials Unit inde-
pendently carried out random allocation of each of 
these groups to the three trial arms. The project team 
were blinded to the allocation during the conduct of the 
trial. Practices were not formally blinded; however, as 
they were not asked for consent, practice staff were not 
aware that they were in a trial. All outcomes were mea-
sured using routinely recorded dispensed prescribing 
data by using pre-defined indicators, neither of which 
could be influenced by practices (except by changing 
their prescribing) or the research team. The trial statis-
ticians were blinded for data cleaning and analysis.
interventions
A detailed description of the development of the inter-
ventions and examples of study materials has been pre-
viously published.20 The two interventions evaluated 
were feedback of prescribing safety data and feedback 
plus a theory informed behavioural change component. 
All practices in each arm received the same intervention 
with no tailoring beyond feedback being specific to 
each practice, and no modifications were made during 
the trial.
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At the start of the trial, all practices received a short 
educational newsletter describing the targeted high risk 
prescribing and recommending that practices review 
patients at potential risk; this was similar to existing 
NHS Scotland material regularly sent to practices. NHS 
Scotland Information Services Division sent the educa-
tional newsletter (appendix 120), which included a link 
to a webpage with downloadable searches to facilitate 
identification of patients in practices’ electronic medi-
cal records and further information about the targeted 
prescribing. Practices in arm 1 received only the educa-
tional newsletter, which is routine practice in NHS Scot-
land, plus support for searching, which is not routine. 
The arm 1 comparator against which the two more 
active interventions were evaluated was therefore mod-
estly enhanced “usual care,” chosen to reflect a simple 
to implement “best practice” comparator and to over-
come health boards’ concerns about identifying poten-
tially risky prescribing and doing nothing whatsoever 
about it.
Practices in arm 2 (feedback) were additionally sent 
feedback of their rate of the targeted prescribing bench-
marked against the rate achieved by the 25% of Scottish 
practices with the most optimal rates in the year before 
feedback started. The choice of benchmark represents 
current practice in NHS Scotland to use a “best in class” 
comparison rather than mean or median performance. 
Feedback design drew on knowledge of factors associ-
ated with greater response and included both presenta-
tion of graphical data showing change over time versus 
the benchmark and a written explanation of why the 
indicators were important and what actions practices 
should take in response. Feedback of practices’ rates of 
the six individual measures of high risk prescribing was 
sent quarterly by email for five rounds for the year June 
2012 to June 2013, with the email signed by senior staff 
in the health board and NHS Scotland Information Ser-
vices Division. Educational material and feedback was 
sent to a single practice email address used by the par-
ticipating health boards to communicate routinely with 
practices, which was either a generic practice email 
address (typically checked by an administrative staff 
member) or the address of the practice manager or a 
nominated prescribing lead (typically a general practi-
tioner). The research team had no direct control over 
what recipients did with the email or attached educa-
tional material or feedback.
Practices in arm 3 (feedback plus theory informed 
behavioural change component) received the same edu-
cational newsletter and feedback, but the feedback 
document additionally included a one page theory 
informed behavioural change component intended to 
increase the likelihood that practices would respond to 
the feedback by searching for and reviewing patients 
receiving the targeted prescribing. We created four dif-
ferent behavioural change components focused on the 
three domains of the theory of planned behaviour (atti-
tudes, subjective norms, and perceived behavioural 
control) and an action planning component based on 
the health action process approach.21 22 Each of the five 
rounds of feedback contained one of these components, 
with the action planning intervention delivered twice. 
Appendix 2 gives examples of the behavioural change 
components, and appendix 3 gives an anonymised 
example of feedback including the action planning 
component (the feedback only arm had a blank page 2 
but was otherwise identical).20
Outcomes
We selected outcomes from measures that had been val-
idated in one or more recent formal consensus stud-
ies,8 23  on the basis of their perceived importance and 
their feasibility to implement using national prescrib-
ing data. Selection was done by the project Steering 
Group, which included representatives from each of the 
three participating health boards, NHS Scotland Infor-
mation Services Division (who manage the national 
data), and the research team. Box 1 lists the six individ-
ual indicators selected. We measured all outcomes by 
using routinely available dispensed prescribing data 
held by NHS Scotland. Measurement was at the level of 
the patient, using binary variables whereby, at the end 
of each quarter, patients with risk factors for adverse 
drug effects (for example, having a prescription for an 
oral anticoagulant) were defined as receiving or not 
receiving a specified high risk prescription in that 
 quarter (for example, prescription of an oral non-steroi-
dal anti-inflammatory drug without gastroprotection). 
The primary outcome was a binary composite measur-
ing the proportion of patients particularly at risk of an 
adverse event from the specified prescribing who 
box 1: primary and secondary outcomes
primary outcome
Proportion of patients included in one or more of the defined six individual secondary 
outcomes (denominator) who receive any high risk prescription (numerator)*
secondary outcomes
•	S1: Proportion of patients aged 75 years and over (denominator) who receive a 
prescription for an oral antipsychotic (numerator)†
•	S2: Proportion of patients aged 65 years and over and currently treated with a 
diuretic and an angiotensin converting enzyme inhibitor or angiotensin receptor 
blocker (denominator) who receive a prescription for an oral non-steroidal 
anti-inflammatory drug (NSAID) (numerator) (the “triple whammy”)
•	S3: Proportion of patients aged 75 years and over (denominator) who receive a 
prescription for an oral NSAID without co-prescription of a gastroprotective drug 
(numerator)
•	S4: Proportion of patients aged 65 years and over and currently treated with aspirin 
or clopidogrel (denominator) who receive a prescription for an oral NSAID without 
co-prescription of a gastroprotective drug (numerator)
•	S5: Proportion of patients currently treated with an oral anticoagulant 
(denominator) who receive a prescription for an oral NSAID without co-prescription 
of a gastroprotective drug (numerator)
•	S6: Proportion of patients currently treated with an oral anticoagulant 
(denominator) who receive a prescription for aspirin or clopidogrel without 
co-prescription of a gastroprotective drug (numerator)
*For all indicators, proportion is defined as numerator/denominator, usually multiplied by 100 to 
convert to percentage
†As proxy of oral antipsychotic prescribing to older people with dementia. The prescribing dataset 
does not include diagnostic data, but our previous analysis of general practice data had shown 
that more than half of patients aged 75 years and over who received a prescription for an 
antipsychotic had a diagnosis of dementia. Given that dementia is under-recorded in this age 
group, our belief was that most over-75s given an antipsychotic would have dementia, and that 
even those without dementia would potentially benefit from having their treatment reviewed24
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received one or more high risk prescriptions defined by 
the six secondary outcomes. The outcomes pre-speci-
fied at trial registration are the same as in the published 
protocol,19 and all are reported in this paper.
patient involvement
The study design drew on qualitative analysis of data 
from interviews with patients carried out during devel-
opment of another intervention targeting safety of pri-
mary care prescribing,25 but there was no patient or 
public involvement in the study design, choice of out-
come measures, or study conduct and no assessment of 
the burden of the intervention on patients. No patients 
were asked to advise on interpretation or writing up of 
results. There are no plans to disseminate the results of 
the research to study participants or the relevant patient 
community.
sample size
We estimated the required sample size by using the 
n4prop function in the CRTSize library in R,26 27  with the 
number of patients per practice (mean 700), the pri-
mary outcome baseline rate (6.1%), and the intra-class 
correlation coefficient (1.26%) all calculated using the 
same routine dataset used to measure outcomes in the 
main trial. The planned primary comparisons in the 
study were the two intervention arms (arm 2 and arm 3) 
compared with usual care (arm 1) at 15 months, each to 
be tested at a significance level of 0.025. With 85 prac-
tices randomised to each arm, the study had 93% power 
to detect a 25% reduction in the percentage of high risk 
prescribing (from 6.1% to 4.5%) between usual care and 
the two intervention arms at the end of the study. We 
chose 25% on the basis of the findings of the PINCER 
intervention,13  for which the closest outcome (non-ste-
roidal anti-inflammatory drug prescribing in people 
with a history of peptic ulcer) had a 42% reduction in 
odds at six months.13 We expected the EFIPPS interven-
tion to be less effective as it was less intense, so we con-
sidered a 25% reduction important enough to use as the 
basis of the sample size calculation.
statistical analysis
We measured outcomes as repeated quarterly cross sec-
tions, meaning that every measurement includes all 
eligible patients (permanently registered and having a 
risk factor for adverse drug effects from the targeted pre-
scribing at the time of measurement). The main trial 
analysis used a multilevel logistic regression model 
comparing the proportion receiving a high risk pre-
scription in the final quarter of the study in each arm, 
adjusted for two variables used to stratify randomisa-
tion (health board and high risk prescribing at base-
line), with the practice identifier as the clustering 
variable. We tested the effect of each intervention arm 
15 months after the intervention was implemented sep-
arately against the usual care arm at the 2.5% signifi-
cance level, to control for an overall 5% significance 
level. We used the R package lme4 to evaluate the 
model. To consider the change in trends over time, we 
used generalised estimating equations to construct a 
change point model using quarterly measurement from 
quarter 1 2011 to quarter 3 2013. Time was centred at 
baseline, scaled to yearly units, and again adjusted by 
the randomisation stratification variables. We then 
modelled the change in slope as the interaction 
between time and study arm in the period after 
 intervention, which was coded as a dummy variable 
that took the value 0 before the intervention and 1 after-
wards. We evaluated the binomial generalised estimat-
ing equations, adjusted for health board and high risk 
prescribing at baseline, by using an unstructured cor-
relation structure to model the temporal correlation in 
the observations for each practice using the R package 
geepack.
Results
The three health boards included 278 primary care prac-
tices, of which 262 (94%) were eligible for inclusion and 
randomised, with 170 659 registered patients particu-
larly vulnerable to harm from the targeted prescribing 
at baseline. Four (1.5%) practices with 948 (0.6%) 
patients at risk at baseline were lost to follow-up owing 
to practices merging or splitting, and data from the 
remaining 258 practices were analysed (fig 1 ). Baseline 
characteristics of practices and patients were similar 
across arms. The mean age of patients at risk was 77 
years, and 44% were male (table 1 ). Across all arms, 
6.0% (95% confidence interval 5.9% to 6.2%) of patients 
particularly vulnerable to harm from the targeted pre-
scribing were receiving a prescription for one or more 
high risk drugs at baseline, varying at individual indica-
tor level from 0.8% (0.7% to 1.0%) for prescription of 
non-steroidal anti-inflammatory drugs without gastro-
protection to people already receiving an oral anticoag-
ulant to 7.8% (7.5% to 8.0%) for prescription of 
non-steroidal anti-inflammatory drugs to older people 
already receiving an angiotensin converting enzyme 
inhibitor/angiotensin receptor blocker and a diuretic 
(table 1).
At baseline, 6.0% of patients particularly vulnerable 
to harm in arm 1 (usual care) were receiving a high risk 
prescription, compared with 5.9% in arm 2 (feedback 
only) and 6.2% in arm 3 (feedback plus theory informed 
behavioural change component), falling to 5.1%, 4.6%, 
and 4.6% by 15 months (table 2). After adjustment for 
the two stratifying variables (health board and third of 
baseline high risk prescribing), the primary analysis 
found an odds ratio for receiving a high risk prescrip-
tion of 0.88 (95% confidence interval 0.80 to 0.96; 
P=0.007) in arm 2 (feedback) compared with arm 1 
(usual care) and of 0.86 (0.78 to 0.95; P=0.002) in arm 3 
(feedback plus theory informed behavioural change 
component) compared with arm 1.
Although the study was not powered to detect differ-
ences in the six individual indicators, in the pre-speci-
fied secondary analysis examining them the estimated 
odds ratios for five of the indicators (S2 to S6) were sim-
ilar to the primary analysis (although only statistically 
significant for four comparisons) (table 2). In contrast, 
we found no evidence of effectiveness for indicator S1 
(prescription of antipsychotics in people aged 75 and 
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over: odds ratios of 1.01 (0.89 to 1.14) for arm 2 versus 
arm 1 and 1.02 (0.90 to 1.15) for arm 3 versus arm 1).
In the pre-specified secondary analysis of change in 
trend in the primary outcome for the three arms, we 
found evidence that the targeted high risk prescribing 
was falling before the intervention (odds ratio for 
change per year before the intervention 0.92, 0.91 to 
0.94). The segmented regression analysis estimates the 
immediate effect of the intervention as the odds ratio 
for the average level of high risk prescribing in the 
quarter after the intervention compared with the quar-
ter before (after adjustment for trend) and the change 
in trend in high risk prescribing expressed as the odds 
ratio for the change in slope over the year of follow-up 
(fig 2  and table 3). In arm 1 (usual care), we saw no sta-
tistically significant immediate change in level of high 
risk prescribing or change in slope after receipt of the 
educational intervention. In arm 2 (feedback), no 
immediate change in level occurred but we saw a sta-
tistically significant and clinically important change in 
slope towards a steeper reduction (odds ratio per year 
of follow-up 0.87, 0.83 to 0.92). In arm 3 (feedback plus 
theory informed behavioural change component), we 
saw an immediate reduction in the level of high risk 
prescribing (odds ratio 0.96, 0.93 to 1.00) and a statisti-
cally and clinically significant change in slope towards 
a steeper reduction (odds ratio per year of follow-up 
0.88, 0.84 to 0.93).
discussion
Feedback of high risk prescribing at practice level in 
both formats was effective at reducing the targeted 
high risk prescribing compared with a simple educa-
tional intervention with support for identifying 
patients, with similar estimated effect sizes for both 
active intervention arms in the primary analysis of 
change from baseline (a 12% reduction on the odds of 
high risk prescribing in the feedback only arm 2 and a 
14% reduction in the feedback plus theory informed 
behavioural change component arm 3). In time trends 
analysis, the targeted prescribing was decreasing 
before intervention in all three arms, possibly as a 
result of the cumulative effect of related regulatory risk 
communications in previous years.24  We found no evi-
dence that the emailed educational material and 
online support for searching in usual care arm 1 had 
any significant effect, consistent with the wider evi-
dence base showing that posted educational material 
is ineffective at changing practice.28 Both of the inter-
vention arms were associated with a change in trend 
towards a faster reduction in high risk prescribing, 
with some evidence that the theory informed 
behavioural change component led to a faster initial 
fall (although no clinically important difference by 
study end). The study was not powered to detect differ-
ences in the six individual indicators, but five had esti-
mated reductions in rates comparable to the overall 
finding for the composite outcome, the exception being 
prescription of antipsychotics in people aged 75 years 
and over, for which we found no evidence of any effect.
strengths and limitations of study
Strengths of the study included that the intervention 
was carefully developed using the process recom-
mended by the Medical Research Council Complex 
Interventions Framework,29  with explicit use of theory 
to create two feedback formats to evaluate. We paid 
close attention to ensuring that the evaluated interven-
tion was embedded in real world practice, and the trial 
itself involved more than 94% of primary care practices 
Assessed for eligibility (n=278)
Randomised (n=262 practices)
Allocated to arm 1: postal educational
material only (88 practices and
55 896 patients at risk at baseline)
Received allocated intervention
(88 practices)
Allocated to arm 2: postal educational
material plus feedback (87 practices and
56 194 patients at risk at baseline)
Received allocated intervention
(87 practices)
Allocated to arm 3: postal educational
material plus feedback plus theory
informed behavioural change
component (87 practices and
58 569 patients at risk at baseline)
Received allocated intervention
(87 practices)
Lost to follow-up
Practice merger or split (2 practices,
497 patients at risk at baseline)
Lost to follow-up
Practice merger or split (1 practice,
170 patients at risk at baseline)
Lost to follow-up
Practice merger or split (1 practice,
281 patients at risk at baseline)
Analysed
86 practices, 58 582 patients
at risk at end of trial
Excluded from analysis (n= 0)*
Analysed
86 practices, 56 478 patients
at risk at end of trial
Excluded from analysis (n= 0)*
Analysed
86 practices, 55 872 patients
at risk at end of trial
Excluded from analysis (n= 0)*
Excluded (n=16):
  CHI completeness <93% (n=15)
  Practice formed aer Jan 2011 (n=1)
Fig 1 | trial profile. CHi=Community Health index (nHs scotland unique patient identifier). *Design was repeated cross 
sectional analysis of routine data from all patients, so all eligible patients were analysed
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in three geographical areas.15  Follow-up used routinely 
collected data, and all eligible patients (those perma-
nently registered and with risk factors for adverse drug 
effects from the targeted prescribing) were included in 
the analysis in all three arms. In contrast to many 
 previous studies in this field,15  analysis used a pre- 
specified primary outcome and was adjusted for base-
line performance. Analysis was limited to change in the 
targeted prescribing, however, and the possibility exists 
of unmeasured harm from stopping targeted drugs, 
table 2 | prevalence of high risk prescribing at end of intervention by allocation arm, and primary analysis of intervention effect. values are numbers 
(percentages) unless stated otherwise
Outcome
arm 1: education plus 
support for searching 
(usual care)
arm 2: as arm 1 
plus feedback
arm 3: as arm 2 plus theory 
informed behavioural 
change component
adjusted odds ratio (95% Ci)*
arm 2 v arm 1 arm 3 v arm 1
primary outcome
Receipt of any high risk prescription 2845/55 872 (5.1) 2587/56 478 (4.6) 2686/58 582 (4.6) 0.88 (0.80 to 0.96); P=0.007 0.86 (0.78 to 0.95); P=0.002
secondary outcomes
S1: aged ≥75 plus antipsychotic 661/34 533 (1.9) 641/33 824 (1.9) 676/36 282 (1.9) 1.01 (0.89 to 1.14); P=0.91 1.02 (0.90 to 1.15); P=0.76
S2: “triple whammy” 1007/15 268 (6.6) 913/14 855 (6.1) 978/15 827 (6.2) 0.91 (0.81 to 1.03); P=0.12 0.91 (0.81 to 1.02); P=0.13
S3: aged ≥75 plus NSAID 797/34 533 (2.3) 637/33 824 (1.9) 748/36 282 (2.1) 0.77 (0.65 to 0.90); P=0.001 0.82 (0.70 to 0.96); P=0.01
S4: antiplatelet plus NSAID 517/27 103 (1.9) 486/28 170 (1.7) 446/28 873 (1.5) 0.88 (0.75 to 1.04); P=0.14 0.82 (0.69 to 0.96); P=0.02
S5: oral anticoagulant plus NSAID 40/6193 (0.6) 38/6294 (0.6) 30/6537 (0.5) 0.92 (0.57 to 1.49); P=0.74 0.73 (0.44 to 1.21); P=0.22
S6: oral anticoagulant plus 
antiplatelet
276/6193 (4.5) 230/6294 (3.7) 202/6537 (3.1) 0.82 (0.68 to 1.00); P=0.05 0.72 (0.58 to 0.87); P<0.001
NSAID=non-steroidal anti-inflammatory drug.
*All models adjusted for two stratification variables (health board and third of primary outcome baseline performance); secondary outcome analyses additionally adjusted for baseline 
performance on each secondary outcome.
†Defined in box 1.
table 1 | baseline characteristics. values are numbers (percentages) unless stated otherwise
arm 1: education plus support 
for searching (n=88 practices; 
n=55 896 patients)
arm 2: as arm 1 plus feedback 
(n=87 practices; n=56 194 
patients)
arm 3: as arm 2 plus theory informed 
behavioural change component 
(n=87 practices; n=58 569 patients)
practices
Mean (SD) list size 6360 (3005) 6538 (3290) 6893 (3388)
Training* 29 (33) 31 (36) 31 (36)
Dispensing* 3 (3) 6 (7) 0 (0)
Mean (SD) QOF achievement* 97.5 (4.2) 98.5 (3.2) 98.5 (2.7)
Median (IQR) No of patients in primary outcome indicator 584 (429) 623 (527) 600 (413)
patients
Median (IQR) age, years 77 (10) 77 (11) 77 (10)
Male sex 24 625 (44.1) 24 847 (44.2) 25 804 (44.1)
Scottish Index of Multiple Deprivation fifth:
 1 (deprived) 9966 (17.8) 10 597 (18.9) 12 102 (20.7)
 2 14 056 (25.1) 15 232 (27.1) 14 204 (24.3)
 3 9959 (17.8) 10 746 (19.1) 9064 (15.5)
 4 7907 (14.1) 7749 (13.8) 8716 (14.9)
 5 (affluent) 11 762 (21.0) 9620 (17.1) 11 907 (20.3)
 Unknown 2246 (4.0) 2250 (4.0) 2576 (4.4)
Urban/rural:
 Urban 47 365 (84.7) 47 440 (84.4) 50 107 (85.6)
 Rural or unknown 8531 (15.3) 8754 (15.6) 8462 (14.4)
Health board A 12 850 (23.0) 13 505 (24.1) 13 941 (23.8)
Health board B 16 093 (28.8) 17 716 (31.5) 19 239 (32.8)
Health board C 26 953 (48.2) 24 973 (44.4) 25 389 (43.3)
Mean (SD) No of drugs/patient 6.1 (3.6) 6.2 (3.7) 6.1 (3.7)
baseline performance
Primary outcome 3332/55 896 (6.0) 3341/56 194 (5.9) 3634/58 569 (6.2)
Secondary outcomes†:
 S1: aged ≥75 plus antipsychotic 691/34 427 (2.0) 697/33 575 (2.1) 741/36 113 (2.1)
 S2: “triple whammy” 1187/15 632 (7.6) 1166/15 341 (7.6) 1326/16 291 (8.1)
 S3: aged ≥75 plus NSAID 1016/34 427 (3.0) 1001/33 570 (3.0) 1176/36 113 (3.3)
 S4: antiplatelet plus NSAID 706/27 519 (3.6) 768/28 479 (2.7) 771/28 297 (2.7)
 S5: oral anticoagulant plus NSAID 55/5715 (1.0) 49/5754 (0.9) 42/5903 (0.7)
S6: oral anticoagulant plus antiplatelet 278/5715 (4.9) 277/5754 (4.8) 258/5903 (4.4)
IQR=interquartile range; NSAID=non-steroidal anti-inflammatory drug.
*Training=accredited for postgraduate general practitioner training; dispensing=dispenses as well as prescribes drugs in rural areas with no pharmacy; QOF achievement=percentage of 
Quality and Outcomes Framework pay for performance points achieved.
†Outcomes are defined in box 1. Benchmark rates used in feedback (those achieved by 25% of Scottish practices with most optimal prescribing in year before feedback started were S1 1.3% 
(median practice rate across all arms 2.2%), S2 4.8% (median 7.2%), S3 1.3% (median 2.9%), S4 1.2% (median 2.4%), S5 0% (median 0.5%), and S6 2.2% (median 4.1%).
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including an increase in pain (although we would 
expect this to lead to further review), an increase in car-
diovascular events from stopping antiplatelets 
(although the indications for dual antiplatelet or com-
bined antiplatelet and anticoagulant are relatively nar-
row and most historical prescribing is not in the context 
of recent thrombotic events), or worsening behavioural 
disturbance if antipsychotics are stopped in people 
with dementia (although the only trial evidence in this 
context does not show harm30 31).
A limitation of the behavioural change component 
was that the resources used to develop it were 
 constrained by what the Advisory Group considered 
would be realistic to use in any future real world NHS 
implementation and by the space and delivery con-
straints of being embedded in the automated feed-
back. However, this is more a constraint of the highly 
pragmatic design brief, which emphasised creation of 
an intervention that could be implemented at scale, 
rather than a limitation of the study. The primary 
analysis did not find any evidence that the addition of 
the low intensity behavioural change intervention led 
to a clinically more important reduction in the tar-
geted prescribing than did feedback alone (a reduc-
tion in odds of 14% versus 12%, although the trial was 
not powered to make this comparison). However, 
given what seems to be a more rapid response to 
 feedback with the implemented behavioural change 
component in the secondary analysis, the additional 
effectiveness of more intense behavioural change 
interventions in this context is an important avenue 
for further research.
An additional limitation shared with almost all feed-
back studies is that whether the effect of the interven-
tion will be sustained once feedback ceases is as yet 
unclear.15 Also, some non-steroidal anti-inflammatory 
drugs and aspirin can be bought over the counter with-
out a prescription, so the targeted high risk prescribing 
of non-steroidal anti-inflammatory drugs and antiplate-
lets is likely to be underestimated both before and after 
the intervention. We also cannot be certain that some 
patients did not replace stopped prescriptions by pur-
chasing their own drugs. Finally, whether feedback 
would be equally effective in reducing other types of 
high risk prescribing is uncertain, particularly given the 
lack of effect on antipsychotic prescribing in older peo-
ple, which is more likely to be initiated by a specialists 
than is the case for non-steroidal anti-inflammatory 
drugs in particular and for which responsibility for 
review may be ambiguous.
Comparison with other studies
Although many trials of data feedback have been con-
ducted in other contexts, previous studies of feedback 
of prescribing safety data have not found feedback to be 
effective (two studies of a single round of feedback 
 combined with an educational intervention targeting 
prescribing of benzodiazepines and non-steroidal 
anti-inflammatory drugs16 18  and one study of three 
rounds of two monthly feedback targeting benzodiaz-
epine prescribing17 ). In contrast, this study showed a 
clinically important reduction in the targeted prescrib-
ing, possibly because of the use of repeated feedback 
from an authoritative NHS organisation over 15 months, 
clear guidance on expected behaviour, and a compari-
son with a “best in class” benchmark that three quar-
ters of practices were not already meeting, all of which 
have been shown to be associated with greater response 
to feedback.15
The observed effect size is smaller than that for two 
higher intensity interventions evaluated in cluster ran-
domised trials in UK primary medical care. In the PIN-
CER trial, the odds ratio for the three primary outcomes 
at six months ranged from 0.51 to 0.73, although unlike 
in our study the effectiveness of the intervention was 
waning by 12 months, with odds ratios for the three 
primary outcomes at 12 months ranging from 0.63 to 
0.91.13  In the DQIP trial, the odds ratio for the primary 
outcome (a composite of nine measures of high risk 
prescribing of non-steroidal anti-inflammatory drugs 
and antiplatelets) was 0.63 (0.57 to 0.68), and this 
effect was sustained in the 12 months after the inter-
vention ceased, reflecting that the intervention 
reduced general practitioners’ subsequent initiation 
of high risk prescribing.14  However, a key advantage of 
automated feedback interventions is that the cost of 
scaling delivery across entire health systems is much 
less than for more intensive interventions. Although 
targeting a different type of prescribing, a recent trial 
of social norm feedback to the 20% of English general 
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Fig 2 | Change in composite high risk prescribing in three 
trial arms
table 3 | immediate change in level and change in trend in composite high risk 
prescribing after intervention*
 Outcome Odds ratio (95% Ci) per year p value
Time trend (change per year before intervention) 0.92 (0.91 to 0.94) <0.001
Change in level of high risk prescribing in quarter immediately after intervention started:
 Arm 1—usual care 0.97 (0.94 to 1.01) 0.10
 Arm 2—feedback 1.00 (0.96 to 1.03) 0.85
 Arm 3—feedback plus behavioural change 
component
0.96 (0.92 to 1.00) 0.05
Change in time trend per year after intervention:
 Arm 1—usual care 0.99 (0.94 to 1.04) 0.72
 Arm 2—feedback 0.87 (0.83 to 0.92) <0.001
 Arm 3—feedback plus behavioural change 
component
0.88 (0.84 to 0.93) <0.001
*Adjusted for two stratification variables (health board and third of primary outcome baseline performance).
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practices with the highest rates of antibiotic prescrib-
ing also showed a small but significant reduction in 
targeted prescribing, consistent with carefully 
designed feedback delivered across large number of 
practices being a reasonable strategy with small but 
important effects.32
An alternative to this type of feedback intervention 
for existing prescribing is point of care reminders or 
alerts. The most recent Cochrane review of the effec-
tiveness of point of care reminders estimated the 
median improvement in prescribing quality or safety 
associated with their implementation to be 3.3%, but 
with considerable heterogeneity across the 21 trials 
examining prescribing outcomes.33  Only three of the 
studies targeted prescribing safety outcomes, with 
effect sizes that were respectively clinically insignifi-
cant,34  similar to this study (10% relative improve-
ment35 ), and somewhat larger than this study (18% 
relative improvement36). However, the considerable 
heterogeneity in outcomes targeted means that the rel-
ative effectiveness of point of care interventions com-
pared with those that prompt review of existing 
prescribing is uncertain, although the two approaches 
are likely to be complementary.
Conclusions and policy implications
This highly pragmatic trial showed the effectiveness 
of a low intensity feedback intervention delivered by 
the NHS and implemented across nearly all practices 
in three geographical areas. With the rapid growth of 
patient level datasets based on electronic medical 
records or pharmacy claims data, the potential for 
feedback interventions to improve prescribing safety 
is considerable, and many healthcare systems could 
deploy similar interventions now. In particular, given 
the relative ease with which feedback can be imple-
mented at scale, it has a highly plausible place as a 
universal core of improvement in safety of prescrib-
ing to be supplemented by other more intensive inter-
ventions in practices that do not respond to feedback 
alone.13 14
The minimum requirements for implementation are 
a patient level prescribing dataset to allow construc-
tion of safety indicators6 8 9 37  and the ability to attri-
bute prescribing either to a practice (which is possible 
in NHS Scotland) or to an individual prescriber (which 
will be feasible in some other contexts). Although pre-
scribing of non-steroidal anti-inflammatory drugs and 
antiplatelets has strong face validity, and this study 
provides evidence that feedback is effective for the 
targeted measures, the choice of indicators for feed-
back should be based on what is known or believed to 
be particularly problematic in the local context of 
implementation. For example, dangerous opiate use 
might be judged to be a more urgent target in North 
America than in the UK, where opiate related deaths 
are much less common reflecting relatively low UK 
prescribing rates of oxycodone, hydrocodone, and 
fentanyl.38 39  However, given the uncertainty about 
whether other prescribing will be equally sensitive to 
feedback, all implementation should aim to evaluate 
effectiveness carefully by using interrupted time 
series methods at a minimum.40 Understanding 
whether effects are sustained when feedback ceases, 
evaluating a range of behavioural change interven-
tions to accompany feedback, and identifying the 
most effective and cost effective blend of lower and 
higher intensity interventions to improve safety of 
prescribing in wider health systems are important 
areas for future research.
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